New CEO At MorphoSys Seeking Partner For ‘CAR-T Killer’ Lymphoma Drug

Company could seal alliance ahead of late Q4 filing

Analysts tip Munich-based company for greatness, but it will need a big pharma partner to take on Roche's Polivy in competitive hemato-oncology market.

Morphosys
Morphosys • Source: Morphosys

European biotech MorphoSys AG has a potential blockbuster on its hands, and with a US Food and Drug Administration filing just weeks away, its new CEO is on the hunt for a commercial partner to help maximise the drug’s potential.

Tafasitamab (formerly MOR208) is a next-generation antibody, dubbed by some a possible "CAR-T killer" in the diffuse large B-cell lymphoma...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip